Estudo randomizado | Rendesivir iniciado precocemente em pacientes ambulatoriais pode prevenir a progressão para Covid-19 grave.

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients – New England Journal of Medicine

Editorial: The Goldilocks Time for Remdesivir — Is Any Indication Just Right?

Comentário: Three days of remdesivir cuts risk for severe COVID-19 in outpatients – MedicalXpress

Comentário no Twitter

Among nonhospitalized patients with Covid-19–related symptoms, a 3-day course of remdesivir resulted in an 87% lower risk of hospitalization or death than placebo. #COVID19 #IDTwitter https://t.co/YFflw5nBxB pic.twitter.com/4NCD9AcnYH

— NEJM (@NEJM) December 22, 2021